Erik A Williams, Isabella Vegas, Fardous F El-Senduny, Jessica Zhang, Douglas A Mata, Matthew C Hiemenz, Sarah R Hughes, Brianna C Sa, Garrett P Kraft, Nicole Gorbatov, Kathleen Foley-Peres, Edward Z Sanchez, Clara Milikowski, Kevin Jon Williams, Jeffrey S Ross, Razelle Kurzrock, Elizabeth A Montgomery, David B Lombard, Surinder Kumar
Myxofibrosarcoma (MFS) is a common soft tissue sarcoma of the elderly that typically shows low tumor mutational burden, with mutations in TP53 and in genes associated with cell cycle checkpoints (RB1, CDKN2A). Unfortunately, no alterations or markers specific to MFS have been identified and, as a consequence, there are no effective targeted therapies. The receptor tyrosine kinase AXL, which drives cellular proliferation, is targetable by new antibody-based therapeutics. Expression of AXL messenger RNA is elevated in a variety of sarcoma types, with the highest levels reported in MFS, but the pathogenic significance of this finding remains unknown...
February 19, 2024: American Journal of Surgical Pathology